Literature DB >> 20095945

What should be considered on design of a colon-specific prodrug?

Yunjin Jung1, Young Mi Kim.   

Abstract

IMPORTANCE OF THE FIELD: Generally, a prodrug, a pharmacologically inactive derivative of an active drug, is designed to modulate pharmacokinetic properties of the parent drug. Targeted distribution of an orally administered drug at the large intestine confers therapeutic advantages on treatment of colonic diseases, peptide and protein therapy and chronotherapy. AREAS COVERED IN THIS REVIEW: To achieve such distribution control in the gastrointestinal tract, the adoption of the prodrug concept gives birth to a colon-specific prodrug. The requirement for a prodrug to be colon-specific is described along with the necessary and sufficient conditions of drugs for conversion to a colon-specific prodrug. The known and previously unnoticed factors that negatively influence therapeutic activity and reproducibility of a colon-specific prodrug are presented with suggestions to minimize the negative influence. WHAT THE READER WILL GAIN: This review provides tactics to satisfy the requirements for being colon-specific and the potential strategies to circumvent obstacles in developing an efficient colon-specific prodrug. TAKE HOME MESSAGE: On design of a colon-specific prodrug, one should take into consideration not only delivery of a drug to the target site, but also the therapeutic effectiveness there.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20095945     DOI: 10.1517/17425240903490401

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  10 in total

Review 1.  Nanomedicine in GI.

Authors:  Hamed Laroui; David S Wilson; Guillaume Dalmasso; Khalid Salaita; Niren Murthy; Shanthi V Sitaraman; Didier Merlin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-12-09       Impact factor: 4.052

2.  Therapeutic switching of sulpiride, an anti-psychotic and prokinetic drug, to an anti-colitic drug using colon-specific drug delivery.

Authors:  Dohoon Kim; Wooseong Kim; Seongkeun Jeong; Dayoon Kim; Jin-Wook Yoo; Yunjin Jung
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

3.  Glycyrrhizin enhances therapeutic activity of a colon-specific methylprednisolone prodrug against experimental colitis.

Authors:  Yonghyun Lee; Seongkeun Jeong; Wooseong Kim; Hyunjeong Kim; Jeong-Hyun Yoon; Seong Hoon Jeong; Yunjin Jung
Journal:  Dig Dis Sci       Date:  2012-11-29       Impact factor: 3.199

4.  Colon-targeted delivery of piceatannol enhances anti-colitic effects of the natural product: potential molecular mechanisms for therapeutic enhancement.

Authors:  Soohwan Yum; Seongkeun Jeong; Sunyoung Lee; Joon Nam; Wooseong Kim; Jin-Wook Yoo; Min-Soo Kim; Bok Luel Lee; Yunjin Jung
Journal:  Drug Des Devel Ther       Date:  2015-08-04       Impact factor: 4.162

5.  Conjugation of metronidazole with dextran: a potential pharmaceutical strategy to control colonic distribution of the anti-amebic drug susceptible to metabolism by colonic microbes.

Authors:  Wooseong Kim; Yejin Yang; Dohoon Kim; Seongkeun Jeong; Jin-Wook Yoo; Jeong-Hyun Yoon; Yunjin Jung
Journal:  Drug Des Devel Ther       Date:  2017-02-14       Impact factor: 4.162

6.  Conjugation of Amisulpride, an Anti-Psychotic Agent, with 5-Aminosalicylic Acid via an Azo Bond Yields an Orally Active Mutual Prodrug against Rat Colitis.

Authors:  Wooseong Kim; Dayoon Kim; Seongkeun Jeong; Sanghyun Ju; Hanju Lee; Soojin Kim; Jin-Wook Yoo; In-Soo Yoon; Yunjin Jung
Journal:  Pharmaceutics       Date:  2019-11-07       Impact factor: 6.321

7.  Evaluation of glycine-bearing celecoxib derivatives as a colon-specific mutual prodrug acting on nuclear factor-κB, an anti-inflammatory target.

Authors:  Sunyoung Lee; Yonghyun Lee; Wooseong Kim; Joon Nam; Seongkeun Jeong; Jin-Wook Yoo; Min-Soo Kim; Hyung Ryong Moon; Yunjin Jung
Journal:  Drug Des Devel Ther       Date:  2015-08-07       Impact factor: 4.162

8.  Celecoxib coupled to dextran via a glutamic acid linker yields a polymeric prodrug suitable for colonic delivery.

Authors:  Yonghyun Lee; Jungyun Kim; Wooseong Kim; Joon Nam; Seongkeun Jeong; Sunyoung Lee; Jin-Wook Yoo; Min-Soo Kim; Yunjin Jung
Journal:  Drug Des Devel Ther       Date:  2015-07-30       Impact factor: 4.162

9.  A colon-specific prodrug of metoclopramide ameliorates colitis in an experimental rat model.

Authors:  Yejin Yang; Wooseong Kim; Dayoon Kim; Seongkeun Jeong; Jin-Wook Yoo; Yunjin Jung
Journal:  Drug Des Devel Ther       Date:  2018-12-28       Impact factor: 4.162

10.  Dapsone Azo-Linked with Two Mesalazine Moieties Is a "Me-Better" Alternative to Sulfasalazine.

Authors:  Changyu Kang; Jaejeong Kim; Sanghyun Ju; Sohee Park; Jin-Wook Yoo; In-Soo Yoon; Min-Soo Kim; Yunjin Jung
Journal:  Pharmaceutics       Date:  2022-03-21       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.